Krystal Biotech, Inc. KRYS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $225.03M+81.5% | $204.83M+130% | $198.91M+280% | $146.73M+38.5% | $123.96M+117% | ||
| $5.78M-1.5% | $5.67M-3.7% | $5.47M-21.4% | $5.37M-21.7% | $5.87M-6.2% | ||
| $54.65M+2.5% | $54.51M+11.0% | $54.11M+18.6% | $54.27M+33.6% | $53.31M+37.4% | ||
| —— | —— | $32.07M-65.9% | $14.14M-86.3% | $62.73M+35.0% | ||
| —— | —— | —— | —— | $11.59M+72.7% | ||
| —— | —— | —— | —— | —— | ||
| $5.39M— | $15.4M— | $17.1M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $3.18M+62.9% | $2.28M+60.7% | $2.38M+212% | $2.2M+274% | $1.95M— | ||
| —— | —— | —— | —— | —— | ||
| $807K+2.3% | $827K+10.7% | $818K+3.7% | $797K-4.1% | $789K-9.1% | ||
| $250.28M+75.4% | $200.87M+57.4% | $176.2M+161% | $195.4M+1,654% | $142.67M+405% | ||
| $12.9M+40.4% | $11.95M+182% | $10.61M+101% | $9.96M+65.4% | $9.18M+19.6% | ||
| $444.77M-12.3% | $422.54M-7.7% | $493.55M+24.3% | $507.71M+30.0% | $507.21M+12.3% | ||
| $390.43M+20.6% | $375.64M+25.8% | $350.37M+12.1% | $333.83M-3.6% | $323.73M-21.5% | ||
| —— | —— | —— | —— | $435K— | ||
| —— | —— | -$153.36M— | -$183.4M— | -$192.23M— | ||
| $5.04M+135% | $0— | $6.97M+69,620% | $3.26M+32,480% | -$14.51M-108% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $3.97M-98.1% | ||
| —— | —— | —— | $922K— | -$474K— | ||
| $192.54M+483% | $151.44M+1,225% | $18.64M+19.2% | $8.04M-90.5% | -$50.24M-122% | ||
| $15.9M+162% | $15.67M+177% | $14.39M+179% | $17.52M+775% | $6.07M— | ||
| -$621K+54.2% | -$498K+70.8% | -$32K+98.5% | -$138K+93.8% | -$1.36M+43.0% | ||
| $5.78M-1.5% | $5.67M-3.7% | $5.47M-9.5% | $5.37M-9.7% | $5.87M+9.8% | ||
| —— | —— | —— | —— | -$12.5M— | ||
| $5.39M— | $15.4M— | $17.1M— | —— | —— | ||
| $23.35M-35.3% | $21.27M-31.0% | $26.22M-8.4% | $29.91M+37.6% | $36.12M+220% | ||
| -$669K+13.1% | -$578K+30.6% | -$629K+25.4% | -$685K+19.9% | -$770K+10.8% | ||
| $3.18M+62.9% | $2.28M+60.7% | $2.38M+212% | $2.2M+274% | $1.95M— | ||
| —— | —— | —— | —— | $11.04M— | ||
| —— | —— | —— | —— | —— | ||
| $807K+2.3% | $827K+10.7% | $818K+3.7% | $797K-4.1% | $789K-9.1% | ||
| $4.98M-21.7% | $5.95M-1.9% | $7.19M+27.7% | $7.47M+34.3% | $6.36M+15.7% | ||
| —— | —— | —— | $333.83M-3.6% | $323.73M-21.5% | ||
| —— | —— | —— | —— | $435K— | ||
| —— | —— | —— | —— | $1.71M— | ||
| —— | —— | —— | —— | $1.8M— | ||
| $237.38M+76.3% | $188.91M+51.8% | $165.59M+161% | $185.44M+1,162% | $134.62M+347% | ||
| $237.38M+76.3% | $188.91M+51.8% | $165.59M+161% | $185.44M+1,162% | $134.62M+347% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Krystal Biotech, Inc. generate?
- Krystal Biotech, Inc. (KRYS) generated $250.3M in operating cash flow over the trailing twelve months.
- What is Krystal Biotech, Inc.'s free cash flow?
- After $12.9M of capital expenditures, Krystal Biotech, Inc.'s free cash flow was $237.4M over the trailing twelve months, up 76.3% year over year.
- Where does Krystal Biotech, Inc.'s cash flow data come from?
- Every line is extracted from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
